Bcl‑2 correlates with localization but not outcome in human osteosarcoma

Trieb,Klemens; Sulzbacher,Irene; Kubista,Bernd

doi:10.3892/ol.2013.1395

Bcl‑2 correlates with localization but not outcome in human osteosarcoma

Authors:
- Klemens Trieb
- Irene Sulzbacher
- Bernd Kubista
View Affiliations

Affiliations: Department of Orthopaedics, Klinikum Wels‑Grieskirchen, Wels A-4600, Austria, Department of Pathology, University Hospital of Vienna, Vienna A-1090, Austria, Department of Orthopaedics, University Hospital of Vienna, Vienna A-1090, Austria
Published online on: June 13, 2013 https://doi.org/10.3892/ol.2013.1395
Pages: 559-561

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

bcl‑2 is a member of the bcl‑2 family that inhibits apoptosis, plays a crucial role in cell viability and is expressed in various types of tumors. With respect to inconsistent results in previous studies, the aim of the present study was to generate a clear hypothesis with regards to the value of bcl‑2 expression as a predictive or prognostic factor in human osteosarcoma. The expression of bcl‑2 was examined immunohistochemically in 49 patients with high‑grade osteosarcoma and the results were correlated with localization, histological response to chemotherapy, survival and the occurrence of metastases. In patients with osteosarcoma, 21/49 cases (43%) were positive for bcl‑2 expression and the remaining cases were negative. A significantly higher expression of bcl‑2 was observed in central tumors located in the pelvis (83 vs. 37% positive; P<0.05). The bcl‑2 expression status revealed no statistically significant correlation with response to chemotherapy, with 57% of patients with bcl‑2‑positive tumors showing a good response and 43% showing a poor response. No significant difference was observed when comparing survival or occurrence in bcl‑2‑positive and ‑negative tumors. In conclusion, the results of the present study indicate that, despite higher bcl‑2 expression in central osteosarcoma, the expression in high‑grade osteosarcoma is not a reliable prognostic or predictive marker.

View Figures

View References

1.	Bielack S, Kempf-Bielack B, Delling G, Exner G, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H and Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar
2.	Davis AM, Bell RS and Goodwin PJ: Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 12:423–431. 1994.PubMed/NCBI
3.	Baldini N, Scotlandi K, Barbanti-Brodano G, Manara M, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S and Campanacci M: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 333:1380–1385. 1995. View Article : Google Scholar : PubMed/NCBI
4.	Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M, Versari M and Bacci G: Evaluation of p-glycoprotein, HER2/ErbB-2, p53, and bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer. 100:1936–1942. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Pakos E and Ioannidis J: The association of p-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis Cancer. 98:581–589. 2003.PubMed/NCBI
6.	Sulzbacher I, Birner P, Trieb K, Traxler M, Lang S and Chott A: Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol. 16:66–71. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Trieb K and Kotz R: Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol. 33:11–17. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Chao D and Korsmeyer S: Bcl-2 family: regulators of cell death. Ann Rev Immunol. 16:395–419. 1998. View Article : Google Scholar
9.	Jäättelä M: Escaping cell death: survival proteins in cancer. Exp Cell Res. 248:30–43. 1999.PubMed/NCBI
10.	Amling M, Pösl M, Bälser I and Delling G: Osteosarcoma - apoptosis and proliferation. Pathologe. 15:337–344. 1994.(In German).
11.	Wang ZX, Yang JS, Pan X, Wang JR, Li J, Yin YM and De W: Functional and biological analysis of Bcl-xL expression in human osteosarcoma. Bone. 47:445–454. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Wu X, Cai ZD, Lou LM and Zhu YB: Expression of p53, BCL-2, and apoptotic index in human osteosarcoma and their correlation with prognosis of patients. Cancer Epidemiol. 36:212–216. 2012. View Article : Google Scholar : PubMed/NCBI
13.	Kaseta MK, Khaldi L, Gomatos IP, Tzagarakis GP, Alevizos L, Leandros E, Papagelopoulos PJ and Soucacos PN: Prognostic value of bax, cytochrome C, and caspase-8 protein expression in primary osteosarcoma. J Surg Oncol. 97:259–266. 2008.
14.	Nedelcu T, Kubista B, Koller A, Sulzbacher I, Mosberger I, Arrich F, Trieb K, Kotz R and Toma CD: Livin and Bcl-2 expression in high-grade osteosarcoma. J Canc Res Clin Oncol. 134:237–244. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop. 153:106–120. 1980.PubMed/NCBI
16.	Salzer-Kuntschik M, Brand G and Delling G: Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe. 4:135–141. 1983.(In German).
17.	Bankfalvi A, Navabi H, Bier P, Böcker W, Jansani B and Schmid K: Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol. 174:223–229. 1994. View Article : Google Scholar : PubMed/NCBI
18.	Kaplan E and Meier P: Nonparametic estimation from incomplete observations. J Am Stat Assoc. 53:457–461. 1958. View Article : Google Scholar